New treatments for diabetic retinopathy

Diabetes, Obesity and Metabolism

Volumn 17, Issue 3, 2015, Pages 219-230

  Das, A ^a,b   Stroud, S ^a   Mehta, A ^a   Rangasamy, S ^c  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b NEW MEXICO VA HEALTH CARE SYSTEM   (United States)

^c TGEN   (United States)

Author keywords

Blood retinal barrier; Diabetes complications; Diabetes mellitus; Diabetic retinopathy; Vascular endothelial growth factor

Indexed keywords

KALLIKREIN INHIBITOR; STEROID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; VASCULOTROPIN INHIBITOR; VASCULOTROPIN A;

BLOOD GLUCOSE MONITORING; BLOOD RETINA BARRIER; BLOOD VESSEL PERMEABILITY; CLINICAL FEATURE; DIABETIC MACULAR EDEMA; DIABETIC RETINOPATHY; DISEASE COURSE; DRUG DELIVERY SYSTEM; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INFLAMMATION; KALLIKREIN KININ SYSTEM; LASER COAGULATION; LOW LEVEL LASER THERAPY; MORTALITY; PATHOPHYSIOLOGY; PIGMENT EPITHELIUM; RETINA DETACHMENT; RETINA SURGERY; REVIEW; STEROID THERAPY; VITRECTOMY; ADULT; ANIMAL; ANTAGONISTS AND INHIBITORS; METABOLISM;

ADULT; ANIMALS; BLOOD-RETINAL BARRIER; DIABETIC RETINOPATHY; HUMANS; LASER THERAPY; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84922058649     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12384     Document Type: Review

References (72)

1. International Diabetes Federation. Diabetes: facts and figures 2013. Available from URL: http://www.idf.org/worlddiabetesday/toolkit/gp/facts-figures. Accessed 19 September 2014.
2. Yau JW, Rogers SL, Kawasaki R et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012; 35: 556-564.
3. Klein R. Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic Epidemiol 2007; 14: 179-183.
4. Klein R, Klein BEK, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1984; 102: 520-526.
5. Klein R, Klein BEK, Moss SE, Davis MD, DeMets DL. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 1984; 102: 527-532.
6. Early Treatment Diabetic Retinopathy Study Research Group. Fundus photographic risk factors for progression of diabetic retinopathy. ETDRS Report # 12. Ophthalmology 1991; 98(Suppl): 823-833.
7. Kuwabara T, Cogan DG. Retinal vascular patterns. VI. Mural cells of the retinal capillaries. Arch Ophthalmol 1963; 69: 492-502.
8. Das A, Frank RN, Weber M et al. ATP causes retinal pericytes to contract in vitro. Exp Eye Res 1988; 46: 349-362.
9. Frank RN. Diabetic retinopathy. N Engl J Med 2004; 350: 48-58.
10. Brownlee M. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 2005; 54: 1615-1625.
11. Das A, McGuire PG. Retinal and choroidal angiogenesis: Pathophysiology and strategies for inhibition. Prog Retin Eye Res 2003; 22: 721-748.
12. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
13. King P, Peacock I, Donnelly R. The UK Prospective Diabetes Study (UKPDS): clinical and therapeutic implications for Type 2 diabetes. Br J Clin Pharmacol 1999; 48: 643-648.
14. The ACCORD, Study Group ACCORD, Eye Study Group. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010; 363: 233-244.
15. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. Br Med J 2011; 343: d4169.
16. Muir KW, Grubber J, Mruthyunjaya P, McCant F, Bosworth HB. Progression of diabetic retinopathy in the hypertension intervention nurse telemedicine study. JAMA Ophthalmol 2013; 131: 957-958.
17. Chaturvedi N, Porta M, Klein R et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet 2008; 372: 1394-1402.
18. Sjølie AK, Klein R, Porta M et al. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet 2008; 372: 1385-1393.
19. Benarous R, Sasongko MB, Qureshi S et al. Differential association of serum lipids with diabetic retinopathy and diabetic macular edema. Invest Ophthalmol Vis Sci 2011; 52: 7464-7469.
20. Keech AC, Mitchell P, Summanen PA et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007; 370: 1687-1697.
21. Davis MD, Fisher MR, Gangnon RE et al. Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: early Treatment Diabetic Retinopathy Study Report #18. Invest Ophthalmol Vis Sci 1998; 39: 233-252.
22. West SD, Groves DC, Lipinski HJ et al. The prevalence of retinopathy in men with type 2 diabetes and obstructive sleep apnoea. Diabet Med 2010; 27: 423-430.
23. Klein R, Klein B. The epidemiology of diabetic retinopathy. In: Ryan SJ, ed. Retina II. London: Elsevier, 2013; 907-924.
24. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema: early treatment diabetic retinopathy study report number 1. Arch Ophthalmol 1985; 103: 1796-1806.
25. Duh EJ, Yang HS, Suzuma I, Miyagi M et al. Pigment epithelium-derived factor suppresses ischemia-induced retinal neovascularization and VEGF-induced migration and growth. Invest Ophthalmol Vis Sci 2002; 43: 821-829.
26. Miura Y, Treumer F, Klettner A et al. VEGF and PEDF secretions [68] over time following various laser irradiations on an RPE organ culture. Invest Ophthalmol Vis Sci 2010; 51: 469.
27. Luttrull JK, Musch DC, Mainster MA. Subthreshold diode micro- pulse photocoagulation for the treatment of clinically significant diabetic macular oedema. Br J Ophthalmol 2005; 89: 74-80.
28. Laursen ML, Moeller F, Sander B, Sjoelie AK. Subthreshold micropulse diode laser in patients with diabetic macular edema. Br J Ophthalmol 2004; 88: 1173-1179.
29. Sivaprasad S, Dorin G. Subthreshold diode micropulse photocoagulation for the treatment of diabetic macular edema. Expert Rev Med Devices 2012; 9: 189-197.
30. Figueira J, Khan J, Nunes S et al. Prospective randomised controlled trial comparing sub-threshold micropulse diode laser photocoagulation and conventional green laser for clinically significant diabetic macular oedema. Br J Ophthalmol 2009; 93: 1341-1344.
31. Vujosevic S, Bottega E, Casciano M et al. Microperimetry and fundus autofluorescence in diabetic macular edema: subthreshold micropulse diode laser versus modified early treatment diabetic retinopathy study laser photocoagulation. Retina 2010; 30: 908-916.
32. Lavinsky D, Cardillo JA, Melo LA Jr et al. Randomized clinical trial evaluating mETDRS versus normal or high-density micropulse photocoagulation for diabetic macular edema. Invest Ophthalmol Vis Sci 2011; 52: 4314-4323.
33. Muqit MM, Henson DB, Young LB et al. Laser tissue interactions. Ophthalmology 2010; 117: 2039.
34. Muqit MM, Gray JC, Marcellino GR et al. Barely visible 10-millisecond pascal laser photocoagulation for diabetic macular edema: observations of clinical effect and burn localization. Am J Ophthalmol 2010; 149: 979-986.
35. Kozak I, Oster SF, Cortes MA et al. Clinical evaluation and treatment accuracy in diabetic macular edema using navigated laser photocoagulator NAVILAS. Ophthalmology 2011; 118: 1119-1124.
36. Barteselli G, Kozak I, El-Emam S, Chhablani J, Cortes MA, Freeman WR. 12-month results of the standardised combination therapy for diabetic macular oedema: intravitreal bevacizumab and navigated retinal photocoagulation. Br J Ophthalmol 2014; 98: 1036-1041.
37. Diabetic Retinopathy Study Research Group. Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. Ophthalmology 1981; 88: 583-600.
38. Chew EY, Ferris FL, Csaky KG etal. The long-term effects of laser photocoagulation treatment in patients with diabetic retinopathy (the early treatment diabetic retinopathy follow-up study). Ophthalmology 2003; 110: 1683-1689.
39. Fong DS, Girach A, Boney A. Visual side effects of successful scatter laser photocoagulation surgery for proliferative diabetic retinopathy: a literature review. Retina 2007; 27: 816-824.
40. Blumenkranz MS, Yellachich D, Andersen DE et al. Semiautomated patterned scanning laser for retinal photocoagulation. Retina 2006; 26: 370-376.
41. Al-Hussainy S, Dodson PM, Gibson JM. Pain response and follow-up of patients undergoing panretinal laser photocoagulation with reduced exposure times. Eye 2008; 22: 96-99.
42. Muqit MM, Young LB, McKenzie R et al. Pilot randomised clinical trial of Pascal TargETEd Retinal versus variable fluence PANretinal 20ms laser in diabetic retinopathy: PETER PAN Study. Br J Ophthalmol 2013; 97: 220-227.
43. Muqit MMK, Marcellino GR, Henson DB et al. Single-session vs multiple-session pattern scanning laser panretinal photocoagulation in proliferative diabetic retinopathy. Arch Ophthalmol 2010a; 128: 525-533.
44. Muqit MM, Marcellino GR, Henson DB et al. Optos-guided pattern scan laser (Pascal)-targeted retinal photocoagulation in proliferative diabetic retinopathy. Acta Ophthalmol 2013; 91: 251-258.
45. Funatsu H, Yamashita H, Ikeda T, Nakanishi Y, Kitano S, Hori S. Angiotensin II and vascular endothelial growth factor in the vitreous fluid of patients with diabetic macular edema and other retinal disorders. Am J Ophthalmol 2002; 133: 537-543.
46. Antonetti DA, Barber AJ, Hollinger LA, Wolpert EB, Gardner TW. Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors. J Biol Chem 1999; 274: 23463-23467.
47. Joussen AM, Murata T, Tsujikawa A, Kirchhof B, Bursell SE, Adamis AP. Leukocyte-mediated endothelial cell injury and death in the diabetic retina. Am J Pathol 2001; 158: 147-152.
48. Do DV, Nguyen QD, Khwaja AA et al. Ranibizumab for edema of the Macula in Diabetes study: 3 year outcomes and the need for prolonged frequent treatment. JAMA Ophthalmol 2013; 131: 139-145.
49. Brown DM, Nguyen QD, Marcus DM et al. RIDE and RISE Research Group. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 2013; 120: 2013-2022.
50. The Diabetic Retinopathy Clinical Research Network. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010; 117: 1064-1077.
51. Diabetic Retinopathy Clinical research Network. Intravitreal ranibizumab for diabetic macular edema with prompt versus deferred laser treatment: three year randomized trial results. Ophthalmology 2012; 119: 2312-2318.
52. Diabetic Retinopathy Clinical Research Network; Writing Committee, Aiello LP et al. Rationale for the diabetic retinopathy clinical research network treatment protocol for center-involved diabetic macular edema. Ophthalmology 2011; 118: e5-e14.
53. Michaelides M, Kaines A, Hamilton RD et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology 2010; 117: 1078-1086.
54. American Society of Retina Specialists (ASRS) News. Industry news - clinical updates. Two-year results of phase 3 VISTA trial of Aflibercept for DME treatment show sustained vision improvement. Available from URL: http://www.asrs.org. Accessed 19 September 2014.
55. Diabetic Retinopathy Clinical Research Network. A comparative effectiveness study of intravitreal aflibercept, bevacizumab and ranibizumab for diabetic macular edema. Available from URL: http://drcrnet.jaeb.org/Studies.aspx. Accessed 4 June 2014.
56. Avery RL, Pearlman J, Pieramici DJ et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006; 113: 1695-1705.
57. Diabetic Retinopathy Clinical Research Network. Prompt panretinal photocoagulation versus intravitreal ranibizumab with deferred panretinal photocoagulation for proliferative diabetic retinopathy. Available from URL: http://clinicaltrials.gov/show/NCT01489189. Accessed 19 September 2014.
58. Rangasamy S, McGuire P, Das A. Diabetic retinopathy and inflammation: novel therapeutic targets. Middle East Afr J Ophthalmol 2012; 19: 52-59.
59. Campochiaro P, Brown DM, Pearson A et al., FAME Study Group. Sustained delivery fluocinolone acetonide vitreous inserts provide benefit for at least 3 years in patients with diabetic macular edema. Ophthalmology 2012; 110: 2125-2132.
60. Cunha-Vaz J, Ashton P, Iezzi R et al., FAME Study Group. Sustained delivery fluocinolone acetonide vitreous implants: long-term benefit in patients with chronic diabetic macular edema. Ophthalmology 2014; 119: 2125-2132.
61. Boyer D. Ozurdex diabetic macular edema study. Paper presented at the Annual Meeting of the America Academy of Ophthalmology, New Orleans, LA, 16-19 November 2013.
62. Diabetic Retinopathy Clinical Research Network. Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction. Ophthalmology 2010; 117: 1087-1093.
63. Diabetic Retinopathy Vitrectomy Study. Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Report No. 5. Arch Ophthalmol 1990; 108: 958-964.
64. Ossadon P, Fagan XJ, Lifshitz T, Levy J. A review of anti-VEGF agents for proliferative diabetic retinopathy. Eye 2014; 28: 510-520.
65. Nguyen Q. Higher anti-VEGF approach. Presented at the World Ophthalmology Congress, Tokyo, Japan, 2-6 April 2014.
66. Rubio R. Long-acting anti-VEGF delivery: How close are we? Presented at the World Ophthalmology Congress, Tokyo, Japan, 2-6 April 2014.
67. Rangasamy S, Srinivasan R, Maestas J, McGuire P, Das A. A potential role of angiopoietin-2 in the alteration of the blood-retinal barrier in diabetic retinopathy. Invest Ophthalmol Vis Sci 2011; 52: 3784-3791.
68. Sfikakis P, Grigoropoulos V, Emfietzoglou I et al. Infliximab for diabetic macular edema refractory to laser photocoagulation. Diabetes Care 2010; 33: 1523-1528.
69. Das A, Rangasamy S, Maestas J, McGuire P. CC Chemokines play an important role in alteration of the blood-retinal barrier in diabetes. ARVO Abstract ARVO Meeting, Ft Lauderdale, FL, 2011, Program# 997.
70. Feener EP. Plasma kallikrein and diabetic macular edema. Curr Diab Rep 2010; 10: 270-275.
71. Chun DW, Heier JS, Topping TM et al. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular oedema. Ophthalmology 2006; 113: 1706-1712.
72. American Academy of Ophthalmology. 2002. Available from URL: http://one.aao.org/asset.axd?id=4b0447c9-24c6-411e-a888-3081553693d2. Accessed 19 September 2014.